Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 4/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.45 |
| ▸ | ITGAL | P20701 | 4/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868458 | 1.00 | ITGB2 (0.45) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL14868421 | 1.00 | ITGB2 (0.45) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL11960320 | 0.91 | LRRK2 (0.45) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL11960334 | 0.88 | HRH3 (0.42) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL14872316 | 0.80 | DPP4 (0.44) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL14872323 | 0.80 | DPP4 (0.44) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL12296242 | 0.80 | DPP4 (0.44) | ITGB2ICAM1ITGALHRH4HRH3 | |
| SCHEMBL11960323 | 0.76 | SMN1; SMN2 (0.46) | HRH4HRH3LRRK2 | |
| SCHEMBL14349228 | 0.75 | ITGB2 (0.52) | ITGB2ICAM1ITGALHRH4LRRK2 | |
| SCHEMBL15274620 | 0.75 | HRH3 (0.42) | ITGB2ICAM1ITGALHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | ITGB2 1071/4885ICAM1 2591/4885ITGAL 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.